The hypoglycemic agent metformin has been found to possess chemopreventive and direct antitumor properties. Several clinical studies worldwide are using it as a monotherapy or as an add-on therapy with chemotherapeutic drugs to determine prospectively its efficacy and safety in treating human cancer. In terms of its mechanism of action, metformin moderately inhibits electron transport in mitochondria to cause increased AMP:ATP ratios, which antagonize gluconeogenesis in hepatocytes, and to promote catabolism in most tissues through activating AMP-activated kinase (AMPK). Inhibition of mammalian target of rapamycin signaling through activation of AMPK has been suggested to mediate the antitumor effects of metformin. However, AMPK-independent growth-inhibitory properties of metformin on tumor cells have also been described, suggesting that antagonizing electron transport per se may be cytostatic or cytotoxic to cancer cells. In addition, metformin was hypothesized to display antiviral and antimalarial effects in 1950s, and recently it has been found to promote the generation of CD8 T memory lymphocytes, suggesting that its immune-activating effects may also contribute to its observed antitumor and chemopreventive properties. Chronic administration of metformin has an acceptable toxicity profile and is well tolerated by millions of patients with type 2 diabetes worldwide, suggesting that this agent could potentially be a therapeutic component with low intensity if given in continuous dosing/frequent usage schedules. These metronomic strategies show that metformin can inhibit tumor angiogenesis and activate antitumor immunity, indicating a potential therapeutic interaction with immune potentiation, antitumor effects, and an acceptable toxicity profile. Here, we review current knowledge on metformin’s signaling, metabolic, and immune effects, as well as data from clinical drug trials, to discuss how the interplay may orchestrate the antitumor effects of this agent, particularly in combination with reducedintensity or metronomic chemotherapeutic use.
Home page > Publications > Papers of Interest > Metronomic in adult > Metformin as a Novel Component of (...)
Metformin as a Novel Component of Metronomic Chemotherapeutic Use: A Hypothesis
In this hypothesis paper the authors Jorge Eduardo Duque, Juliana Velez, Ismael Samudio and Enoch Lai from the Grupo de Terapia Celular y Molecular, Pontificia Universidad Javeriana, Bogotá DC, Colombia, the Centro Oncológico de Antioquia, Medellín, Colombia and the Shuang Ho Medical Hospital, Taipei Medical University, Taipei, Taiwan disucss the rationale to "reposition" metformine, an oral hypoglycemic agent as an anticancer agent and its combination with metronomic chemotherapy.
I agree with your hypothesis. Moreover, we are presently carrying out some preliminary experiments in murine breast cancer models pointing to demonstrate the utility of metronomic chemotherapy combined with metformin treatment.
Reply to this message
great ! we can’t wait to see the results. Are these data going to be published soon?
Reply to this message
We dont’ have yet enough data to publish the results obtained. What I can say up to now is that combined oral administration of ciclophosphamide and metformin showed significant antitumor effect with a very significant increase in the animals’ survival and with no apparent toxicity, in a mammary adenocarcinoma tumor model. Those results will be presented in a scientific meeting very soon. Experiments for determinig mechanistic issues are planned but still lacking (...waiting for economic support).
Reply to this message